Autolus Therapeutics (NASDAQ:AUTL) Trading Up 3.7%

Shares of Autolus Therapeutics plc (NASDAQ:AUTL) shot up 3.7% during mid-day trading on Thursday . The stock traded as high as $5.25 and last traded at $5.02. 215,735 shares traded hands during trading, a decline of 86% from the average session volume of 1,496,267 shares. The stock had previously closed at $4.84.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on AUTL. Truist Financial raised their price target on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, April 9th. Needham & Company LLC reissued a “buy” rating and issued a $9.00 target price on shares of Autolus Therapeutics in a research report on Friday, April 12th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $8.16.

Autolus Therapeutics Stock Down 5.8 %

The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -3.80 and a beta of 1.90. The stock has a 50 day simple moving average of $5.89 and a 200 day simple moving average of $5.09.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.18). As a group, analysts forecast that Autolus Therapeutics plc will post -0.71 EPS for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

Several institutional investors have recently modified their holdings of AUTL. Perpetual Ltd boosted its stake in Autolus Therapeutics by 8.2% during the 1st quarter. Perpetual Ltd now owns 2,234,515 shares of the company’s stock valued at $14,256,000 after purchasing an additional 169,784 shares during the period. Goldman Sachs Group Inc. grew its holdings in Autolus Therapeutics by 97.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 131,731 shares of the company’s stock worth $848,000 after buying an additional 64,910 shares in the last quarter. Perceptive Advisors LLC bought a new position in Autolus Therapeutics in the 4th quarter worth approximately $11,793,000. Sierra Summit Advisors LLC acquired a new stake in Autolus Therapeutics in the 4th quarter valued at approximately $275,000. Finally, Price T Rowe Associates Inc. MD bought a new stake in Autolus Therapeutics during the 4th quarter valued at $19,328,000. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.